Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 2.72 g/t Au over 139.9 metres at Golden Summit (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd > New Press Release - StageZero Life Sciences, Ltd. Special and Annual General Meeting Conference Call
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(39)
•••
Comment by telmanon Jun 05, 2023 6:22pm
123 Views
Post# 35481354

RE:New Press Release - StageZero Life Sciences, Ltd. Special and Annual General Meeting Conference Call

RE:New Press Release - StageZero Life Sciences, Ltd. Special and Annual General Meeting Conference Calldarn, I will be driving back home then.

Well that is if they actually have this meeting on June 7.  Maybe tomorrow they will come out with another NR saying how the meeting is postponed! 

Can someone please try to call in and ask about the $4M per year from CARE news release and how that was a total lie as per the last conference call.  We have an oportunity to push them on this and I would rather not wait until the next call 3 or however many months from now.

Might be nice to take some of the wind out of Tripp's sails seeing how he will not be voted out at all.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities